Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PD-0299685 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PD-0299685 | DRUG | - |
Inclusion Criteria: * Postmenopausal as defined by 6 months of spontaneous amenorrhea with serum FSH levels \>40mlU/ml and estradiol \< than = 25 pg/mL or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy and FSH levels \> 40 mlU/ml and estradiol \< than = 25 pg/mL * Women r...
PD-0299685 is an investigational small molecule being developed for the treatment of hot flashes, also known as vasomotor symptoms, associated with menopause. It is being studied in the endocrine therapeutic area.
PD-0299685 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
PD-0299685 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed.
PD-0299685 has been studied in one completed Phase 2 clinical trial, identified as NCT00314964. This trial evaluated the drug for the treatment of vasomotor symptoms (hot flashes) associated with menopause and enrolled 527 female participants aged 40 years and older.
PD-0299685 is the primary name for this investigational drug. No alternative names have been disclosed for this compound.